May 2008
Volume 49, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2008
Long-Term Functional and Morphological Results After Bevacizumab (Avastin®) Treatment of Retinal Angiomatous Proliferations in AMD
Author Affiliations & Notes
  • K. Spasovska
    Ophthalmology, Regensburg Univ Med Ctr, Regensburg, Germany
  • B. Fink
    Ophthalmology, Regensburg Univ Med Ctr, Regensburg, Germany
  • B. Lustinger
    Ophthalmology, Regensburg Univ Med Ctr, Regensburg, Germany
  • H. Helbig
    Ophthalmology, Regensburg Univ Med Ctr, Regensburg, Germany
  • M.-A. Gamulescu
    Ophthalmology, Regensburg Univ Med Ctr, Regensburg, Germany
  • Footnotes
    Commercial Relationships  K. Spasovska, None; B. Fink, None; B. Lustinger, None; H. Helbig, None; M. Gamulescu, None.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science May 2008, Vol.49, 310. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      K. Spasovska, B. Fink, B. Lustinger, H. Helbig, M.-A. Gamulescu; Long-Term Functional and Morphological Results After Bevacizumab (Avastin®) Treatment of Retinal Angiomatous Proliferations in AMD. Invest. Ophthalmol. Vis. Sci. 2008;49(13):310. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : Retinal angiomatous proliferations (RAP) constitute a distinct entity of exudative age-related macular degeneration (AMD), often misinterpreted as occult or minimal classic choroidal neovascularisations (CNV). Because of the developing retinal-choroidal anastomoses with high blood flow, therapy was often unrewarding with progression or recurrences of the RAP. The purpose of this work is to describe long-term functional and morphological outcome of patients treated with intravitreal bevacizumab.

Methods: : Retrospective case series of seventeen patients with RAP. After informed consent, all patients received initially three intravitreal bevacizumab injections (1,25mg/0,1ml) every 4 weeks. Follow-up ranged from 1 to 9 months after the third injection (mean 3,76 months) and comprised best corrected visual acuity (BCVA), ophthalmologic examination, fluorescein angiography and optical coherence tomography.

Results: : Triple intravitreal bevacizumab injections resulted in a stabilisation of BCVA during the first three months (logMAR 0,88 before treatment and 0,82 at month 3). Mean BCVA increased by one line (logMAR 0,73) two to three months after the upload phase. 5 patients (29,4%) needed retreatment at months 5 or 6, two of them were also retreated at month 9. Central retinal thickness in OCT regressed slightly but did not reach statistical significane and was maintained over time.

Keywords: retinal neovascularization • vascular endothelial growth factor • age-related macular degeneration 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×